Top Pharma and Innovative Biotech Presentations at the 2024 Immuno-Oncology Summit

Discover Presentations from industry pioneers, thought leaders, and influencers as they converge to showcase the latest breakthroughs in cancer immunology.


Development of ex vivo Precision Gene-Engineered B Cell-Medicines That Produce Highly Active and Sustained Levels of Transgenic Anti-Tumor Biologics
Sean P. Arlauckas, PhD, Associate Director, Cell Therapy Platform, Be Biopharma Inc.

Uncovering Heterogeneity in Specific Immune Cell Populations in the Tumor Microenvironment
Shahin Aslam, Associate Principal Scientist, Merck

Combined PD-L1/TGFβ Blockade Allows Expansion and Differentiation of Stem Cell–Like CD8 T Cells in Immune-Excluded Tumors
Alessandra Castiglioni, PhD, Scientific Manager, Cancer Immunology, Genentech Inc.

TALEN-Based Platform for Generation of Gene-Edited iPSC-Derived Natural Killer Cells with Improved Functions
An-Ping Chen, PhD, Associate Director, R&D, Cytovia Therapeutics

Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR T Therapies
Nagendra V. Chemuturi, PhD, Senior Director, Eli Lilly and Company

The Advantages of CAR Tscm-Rich Allogeneic Approaches in Oncology
Julia A Coronella, PhD, VP Immuno Oncology, Immuno Oncology, Poseida Therapeutics Inc

Lymph Node–Targeted Vaccine-Boosting of TCR T Cell Therapy Enhances Antitumor Function and Eradicates Solid Tumors
Peter C. DeMuth, PhD, CSO, Elicio Therapeutics

ABBV-184: A Novel Survivin-Specific CD3 Bispecific T Cell Engager Is Active against Both Solid Tumor and Hematological Malignancies
Feng Dong, PhD, Principal Research Scientist II, Foundational Immunology, AbbVie Cambridge Research Center

Benefit and Risk Considerations for Dose Optimization in Immuno-Oncology
Mohamed Elmeliegy, PhD, Director Clinical Pharmacology, Clinical Pharmacology, Pfizer Inc.

Regulation of Myeloid Cells to Induce Tertiary Lymphoid Structures in the TME
Elizabeth Evans, PhD, COO & Senior Vice President, Discovery & Translational Medicine, Vaccinex

A Phase 1/2 Clinical Trial of KVA12123, an Engineered IgG1 Targeting VISTA, as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors
Thierry Guillaudeux, PhD, CSO, Kineta, Inc.

In Vivo Generation of CAR T and NK Cells Utilizing an Engineered Lentiviral Vector
Philip R. Johnson, MD, CEO, Interius Biotherapeutics

Engineering Next-Gen CAR T Cells: Leveraging mRNA for Optimal T Cell Design
Stella Khiew, PhD, Senior Scientist, Merck & Co.

Therapeutic Potency of SAIL66—A Next-Generation T Cell Engager—Against CLDN6-Positive Tumors
Naoki Kimura, PhD, Scientist, Discovery Pharmacology, Chugai Pharmaceutical Co. Ltd.

Development of a High-Throughput 3D Culture Model of Immune-Excluded Tumor Microenvironments
Joanna Y. Lee, PhD, Principal Scientist, Biochemical & Cellular Pharmacology, Genentech

An Autologous Process Generates Genetically Engineered T Cells with Enriched T Memory Stem Cells and Improved Quality Attributes
Yijun Liu, PhD, Associate Director, Cell Biology, Kite Pharma

Infiltrating Solid Tumor Stromal Barriers with Trispecific Antibodies
Maria P. MacWilliams, PhD, Vice President Molecular Biology, Tavotek Biotherapeutics

KEYNOTE PRESENTATION: mRNA Therapeutics in Cancer: Coming of Age
Robert S. Meehan, MD, Senior Director, Clinical Development, Moderna

Ramifications of Tethering T Cell-Activating Cytokines to the Surface of Tumor Cells
John B. Mumm, PhD, Founder & CEO, Deka Biosciences

Intensification of iPSC GdT/NK Product Manufacturing for IO
Yu Qian, PhD, Senior Scientist & Analytical Lead, Cellular Product Development, Takeda Pharmaceuticals Inc.

Computational Approaches to Identifying Targetable Antigens for Personalized Cancer Immunotherapies
Thomas Trolle, PhD, Director, Bioinformatics & AI/ML, Evaxion Biotech A/S

Design Meets Biology: Importance of Avidity versus Geometry in Engineering T Cell Engagers
Even Walseng, PhD, Associate Director Biologics Engineering, Biologics Engineering, AstraZeneca

Translational PK/PD and the First-in-Human Dose Selection of a PD1/IL15 Targeted Cytokine: An Engineered Recombinant Fusion Protein for Cancer Immunotherapy
Rajbharan Yadav, PhD, Senior Principal Scientist, Development Sciences, Genentech

Personalized Neoantigen-Based DNA Vaccine in Combination with Pembrolizumab for Treating Patients with Advanced Hepatocellular Cancer
Jian Yan, PhD, Vice President, Research & Discovery, Geneos Therapeutics


Preliminary Agenda

Conference Programs